This paper is marked retracted in the scholarly record (OpenAlex). Interpret its findings with caution.
RETRACTED: El-Masry et al. Potential Antitumor Activity of Combined Lycopene and Sorafenib Against Solid Ehrlich Carcinoma via Targeting Autophagy and Apoptosis and Suppressing Proliferation. Pharmaceuticals 2024, 17, 527
Thanaa A. El-Masry, Maysa M. F. El-Nagar, Nageh A. El Mahdy, Fatemah A. Alherz, Reham Taher, Enass Y. Osman
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAntioxidant Activity and Oxidative Stress · Cancer, Lipids, and Metabolism · Curcumin's Biomedical Applications
The journal retracts the article “Potential Antitumor Activity of Combined Lycopene and Sorafenib against Solid Ehrlich Carcinoma via Targeting Autophagy and Apoptosis and Suppressing Proliferation” [1] cited above.
Following publication, concerns were brought to the attention of the Editorial Office regarding the integrity of a number of images presented in this publication [1].
Adhering to our standard procedure, an investigation was conducted by the Editorial Office and Editorial Board that identified irregularities and partial duplication in Figures 2–4 presented in this article. While the authors collaborated with this process, full raw material meeting the journal’s requirements for original images (https://www.mdpi.com/journal/pharmaceuticals/instructions#oriimages, accessed on 3 December 2025) could not be provided for evaluation by the Editorial Board. Consequently, the Editorial Board has lost confidence in the reliability of the findings and has decided to retract this publication, as per MDPI’s retraction policy (https://www.mdpi.com/ethics#_bookmark30, accessed on 3 December 2025).
This retraction was approved by the Editor-in-Chief of the journal Pharmaceuticals.
The authors disagreed to this retraction.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1El-Masry T.A. El-Nagar M.M.F. El Mahdy N.A. Alherz F.A. Taher R. Osman E.Y. RETRACTED: Potential Antitumor Activity of Combined Lycopene and Sorafenib against Solid Ehrlich Carcinoma via Targeting Autophagy and Apoptosis and Suppressing Proliferation Pharmaceuticals 20241752710.3390/ph 1704052738675487 PMC 11055160 · doi ↗ · pubmed ↗